Tsubota Laboratory Inc
TSE:4890
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Tsubota Laboratory Inc
TSE:4890
|
JP |
|
E
|
Emimen Co Ltd
TSE:9237
|
JP |
|
Athena Gold Corp
OTC:AHNR
|
US |
|
B
|
Bsm Chemical Co Ltd
SZSE:300796
|
CN |
|
China Literature Ltd
HKEX:772
|
CN |
|
Investors Title Co
NASDAQ:ITIC
|
US |
|
AngloGold Ashanti Ltd
NYSE:AU
|
ZA |
|
B
|
BaTeLab Co Ltd
HKEX:2149
|
CN |
|
P
|
People & Technology Inc
KOSDAQ:137400
|
KR |
|
United Van Der Horst Ltd
BSE:522091
|
IN |
|
Seah Steel Holdings Corp
KRX:003030
|
KR |
Tsubota Laboratory Inc
Tsubota Laboratory Inc is a JP-based company operating in Pharmaceuticals industry. The company is headquartered in Shinjuku, Tokyo-To and currently employs 9 full-time employees. The company went IPO on 2022-06-23. Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The firm operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The firm is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Tsubota Laboratory Inc is a JP-based company operating in Pharmaceuticals industry. The company is headquartered in Shinjuku, Tokyo-To and currently employs 9 full-time employees. The company went IPO on 2022-06-23. Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The firm operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The firm is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
